PCSK9 and myocardial infarction: The low overall incidence rates of myocardial infarction (0.7%) and stroke (0.3%) reported in this study are consistent with those of a previous randomized controlled trial in which PCSK9 inhibition with evolocumab reduced the overall rate of myocardial infarction and stroke in patients with atherosclerotic CVD.16